Alvotech and Bioventure Announces Approval of AVT02 in Egypt

Alvotech and Bioventure, a company owned completely by GlobalOne Healthcare Holding LLC, have declared that the Egyptian Drug Authority (EDA) has given its approval for the production and distribution of AVT02 (adalimumab), a biosimilar for Humira®. AVT02 is commonly used to treat rheumatoid arthritis and various other inflammatory diseases. It will be marketed under the name Adalimumab-EVA?. A biosimilar refers to a medicinal product that is very similar to an approved biologic medicine or reference product, with no important differences in terms of clinical impact. The development and progress in biologics have resulted in innovative and life-altering treatments for various chronic illnesses across multiple therapeutic areas.

The arrival of biosimilars often results in more people using the medicine because it becomes cheaper, allowing more patients to have it [1]. Bioventure and Alvotech are working closely together to bring AVT02 (adalimumab) and other biosimilar candidates to the Middle East and North Africa. Alvotech focuses on developing and producing the medicines, while Bioventure takes charge of making them available to the market.

The collaboration previously declared the authorization of AVT02 in Saudi Arabia, where it will be promoted as Simlandi?.